Security key
G76279101
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 569,136,749
- Total 13F value
- $6,567,461,922
- Share change
- +18,202,784
- Put/Call ratio
- 199%
- SEC-reported price per share
- $11.54
- Number of holders
- 291
- Value change
- +$223,573,966
- Number of buys
- 170
- Number of sells
- 122
- Shares outstanding
- 722,990,037
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
291
Top holders
10
ROIV full security history
Ownership snapshot
Full 13F holder table
Roivant Sciences Ltd. SEC filings
Roivant Sciences Ltd. company facts
Roivant Sciences Ltd. 13D/G history
Broader feeds
Ownership snapshot
Top reported holders of ROIV - Roivant Sciences Ltd. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Dexcel Pharma Technologie...
Disclosed value leader
Dexcel Pharma Technologie...
Comparable rows
0/15
Latest evidence
30 Jun 2024
3/4/5
13F
Highest disclosed value: $1,064,491,735
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Dexcel Pharma Technologies Ltd. has the largest disclosed position value at $1.06B.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Dexcel Pharma Technologies Ltd.'s linked filing trail.
Disclosed position value
Top 5
Dexcel Pharma Technologies Ltd.
$1.06B
SVF Investments (UK) Ltd
$755.88M
Sumitomo Chemical Co., Ltd.
$737.45M
VIKING GLOBAL INVESTORS LP
$730.98M
VIKING GLOBAL PERFORMANCE LLC
$133.35M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Dexcel Pharma Technologies Ltd. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$1,064,491,735
102,849,443 shares
|
— | 10 Nov 2022 |
| SVF Investments (UK) Ltd |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$755,877,753
73,031,667 shares
|
— | 28 Sep 2023 |
| Sumitomo Chemical Co., Ltd. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$737,448,709
71,251,083 shares
|
— | 22 Jun 2023 |
| VIKING GLOBAL INVESTORS LP |
13F
3/4/5
Company · 10%+ Owner
|
—
denominator unverified
|
$730,977,292
69,155,846 shares
|
— | 30 Jun 2024 |
| VIKING GLOBAL PERFORMANCE LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$133,352,577
12,884,307 shares
|
— | 22 Jun 2023 |
| SB INVESTMENT ADVISERS (UK) LTD |
13F
Company
|
—
denominator unverified
|
$754,289,871
71,361,388 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
291
Shares
569,136,749
Rows available
291
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
293
Q3 2024 holders
291
Holder diff
-2
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|